[Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone]

Z Rheumatol. 1996 Mar-Apr;55(2):127-32.
[Article in German]

Abstract

We describe a 28-year-old woman with primary Sjögren's syndrome who had a miscarriage in the 10th week of gestation in December 1993. In her second pregnancy plasma hyperviscosity and high antibody reactivities to 52/60 kD Ro(SS-A) and La(SS-B) represented elevated risk factors for abortion and fetal congenital heart block. Therefore, we performed plasmapheresis and administered dexamethason. At the end of 37th week of gestation a healthy boy was born by caesarean operation. Interestingly, antibody levels to the anti-Ro(SS-A)/La(SS-B) complex showed an increase during both pregnancies with a decline after the abortion as well as the partus. The combined therapy led to a decrease in both the autoantibody reactivities to 52 kD Ro(SS-A) and La(SS-B) and the plasmaviscosity. Plasmapheresis and dexamethason are safe treatment modalities in identified high risk pregnancies for the birth of a child with CHB.

MeSH terms

  • Abortion, Missed / diagnostic imaging
  • Abortion, Missed / immunology
  • Anti-Inflammatory Agents / administration & dosage*
  • Autoantibodies / blood
  • Blood Viscosity / immunology
  • Combined Modality Therapy
  • Dexamethasone / administration & dosage*
  • Female
  • Humans
  • Infant, Newborn
  • Male
  • Plasmapheresis*
  • Pregnancy
  • Pregnancy Complications / immunology
  • Pregnancy Complications / therapy*
  • Pregnancy Outcome
  • Pregnancy, High-Risk*
  • Sjogren's Syndrome / immunology
  • Sjogren's Syndrome / therapy*
  • Ultrasonography, Prenatal

Substances

  • Anti-Inflammatory Agents
  • Autoantibodies
  • Dexamethasone